Driving a New Generation of Cell-based Medicines

Latest MaxCyte News

July 26, 2021
MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market

July 12, 2021
MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing

July 12, 2021
Financial information in the Form S-1 registration statement & Change to Board of Directors

June 15, 2021
MaxCyte Adds Two New Non-Executive Directors to Its Board

May 25, 2021
Celularity and MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates

May 14, 2021
Proposed Dual-Listing on Nasdaq

February 23, 2021
MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences

January 11, 2021
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs

November 9, 2020
MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences

October 13, 2020
MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments

September 10, 2020
MaxCyte to Present at Upcoming 2020 H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference

September 9, 2020
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer

June 25, 2020
MaxCyte® Initiates Launch of New ExPERT™ Range of Expanded Research and GMP Grade Disposables for Complex Cellular Engineering

June 22, 2020
MaxCyte to Present at 2020 European Biotech Investor Day

May 18, 2020
MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting

May 7, 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement

April 9, 2020
MaxCyte Provides Business Update Related to COVID-19 Pandemic

April 6, 2020
MaxCyte to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference

March 24, 2020
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to
Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies

February 5, 2020
MaxCyte’s CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York

2020 Webinar Series

Flexible, clinically adaptable, non-viral approaches to CAR TCR methodologies
August 04, 2020 11:00 AM EDT

View this webinar

Scalable Manufacturing and Nanovesicle Delivery of CRISPR-Cas9 Ribonucleoproteins Using a cGMP- Compliant Cell Engineering Platform
September 17, 2020 8:00 AM PT

View this webinar

Dr. Mark DeWitt, a leading industry expert, shares his secrets on success with the development of a CRISPR/Cas9-based strategy
October 15, 2020 11:00 AM EDT

View this webinar


Winning the Race: Decreasing Protein Development Timelines with Scalable Cell-Engineering
April 15, 2019

Latest Industry News

BIO CEO Defends Dr. Fauci, Says Criticisms “Undermine Our Response to this Pandemic”

In response to attacks on Dr. Anthony Fauci’s credibility and character, BIO President and CEO Dr. Michelle McMurry-Heath issued the following statement:”

July 16, 2020

STAT: First Opinion

A new biotechnology and pharmaceutical industry commitment to patients and the public.

January 8, 2020

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018.

February 25, 2019

BIO’s Workforce Development, Diversity & Inclusion Principles

MaxCyte has committed itself to fostering workplace development, diversity, and inclusion (WDDI) at MaxCyte and across the biotechnology industry. We are dedicated to being at the forefront of efforts to develop a diverse and talented global workforce. To that end, we affirmatively support the following WDDI Principles adopted by the Biotechnology Innovation Organization (BIO), and pledge to do our part to foster diversity and inclusion among our employees, customers, and patients.

February 6, 2018

BIO News: Champion the Biotechnology Industry

See BIO’s latest periodic updates on key issues facing the advancement of science and the ability of researchers and entrepreneurs to deliver the latest medical and biological breakthroughs to people who need them around the world.

July 26, 2017

BIO News: Saving Lives & Transforming Healthcare in the 21st Century

Learn about the impact of biotechnology on patients and society, as well as the factors needed to keep the innovation engine running strong.

April 7, 2017

Twitter Feed News

MaxCyte is excited to take part in today’s @Nasdaq closing bell ceremony! At 3:50pm ET head over to Nasdaq’s livestream to view our leadership team ring the closing bell: https://t.co/JbgRD9ajMz. https://t.co/4ho6haLZrq MaxCyte_info photo

Congratulations to our partner, @VorBioPharma, on the Fast Track designation from the @US_FDA to their lead engineered hematopoietic stem cell (eHSC) therapy, VOR33. #AML https://t.co/Mmi4TqiQqm
MaxCyte_info photo
Vor Biopharma @VorBioPharma
Today we announced that the U.S. FDA granted Fast Track designation to our lead engineered hematopoietic stem cell (eHSC) therapy, VOR33. The Phase 1/2a trial of VOR33 is actively enrolling patients for the treatment of #AML. Read more here: https://t.co/5EWDZJiOvd https://t.co/HIL2OPqehR

Now available to all MaxCyte customers, the new R-50x8 Multi-well Processing Assembly: https://t.co/dS3DPhO001

We're excited to share that MaxCyte has signed a clinical and commercial license with Sana Biotechnology. Sana will use our #FlowElectroporation technology and ExPERT platform to drive its ex vivo #celltherapy plans, strengthening the cell therapy market. https://t.co/F31VS4bfFX

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up